149 related articles for article (PubMed ID: 20013528)
1. Polycystic ovarian syndrome and the risk of cardiovascular disease and thrombosis.
Mak W; Dokras A
Semin Thromb Hemost; 2009 Oct; 35(7):613-20. PubMed ID: 20013528
[TBL] [Abstract][Full Text] [Related]
2. Adolescents with Classical Polycystic Ovary Syndrome Have Alterations in the Surrogate Markers of Cardiovascular Disease but Not in the Endothelial Function. The Possible Benefits of Metformin.
Fruzzetti F; Ghiadoni L; Virdis A; De Negri F; Perini D; Bucci F; Giannarelli C; Gadducci A; Taddei S
J Pediatr Adolesc Gynecol; 2016 Oct; 29(5):489-495. PubMed ID: 27018756
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome.
Toulis KA; Goulis DG; Mintziori G; Kintiraki E; Eukarpidis E; Mouratoglou SA; Pavlaki A; Stergianos S; Poulasouchidou M; Tzellos TG; Makedos A; Chourdakis M; Tarlatzis BC
Hum Reprod Update; 2011; 17(6):741-60. PubMed ID: 21628302
[TBL] [Abstract][Full Text] [Related]
4. Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome.
Mannerås-Holm L; Baghaei F; Holm G; Janson PO; Ohlsson C; Lönn M; Stener-Victorin E
J Clin Endocrinol Metab; 2011 Apr; 96(4):1068-76. PubMed ID: 21252248
[TBL] [Abstract][Full Text] [Related]
5. [Polycystic ovary syndrome: an example of obesity-related cardiovascular complication affecting young women].
Orio F; Cascella T; Giallauria F; Palomba S; De Lorenzo A; Lucci R; Ambrosino E; Lombardi G; Colao A; Vigorito C
Monaldi Arch Chest Dis; 2006 Mar; 66(1):48-53. PubMed ID: 17125045
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular disease risk factors in polycystic ovary syndrome.
Dokras A
Semin Reprod Med; 2008 Jan; 26(1):39-44. PubMed ID: 18181081
[TBL] [Abstract][Full Text] [Related]
7. Do women with polycystic ovary syndrome have an increased risk of cardiovascular disease? Review of the evidence.
Talbott EO; Zborowskii JV; Boudraux MY
Minerva Ginecol; 2004 Feb; 56(1):27-39. PubMed ID: 14973408
[TBL] [Abstract][Full Text] [Related]
8. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease.
Meyer C; McGrath BP; Teede HJ
J Clin Endocrinol Metab; 2005 Oct; 90(10):5711-6. PubMed ID: 16046590
[TBL] [Abstract][Full Text] [Related]
9. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis.
Shroff R; Kerchner A; Maifeld M; Van Beek EJ; Jagasia D; Dokras A
J Clin Endocrinol Metab; 2007 Dec; 92(12):4609-14. PubMed ID: 17848406
[TBL] [Abstract][Full Text] [Related]
10. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society.
Wild RA; Carmina E; Diamanti-Kandarakis E; Dokras A; Escobar-Morreale HF; Futterweit W; Lobo R; Norman RJ; Talbott E; Dumesic DA
J Clin Endocrinol Metab; 2010 May; 95(5):2038-49. PubMed ID: 20375205
[TBL] [Abstract][Full Text] [Related]
11. Long-term consequences of polycystic ovary syndrome on cardiovascular risk.
Rizzo M; Berneis K; Spinas G; Rini GB; Carmina E
Fertil Steril; 2009 Apr; 91(4 Suppl):1563-7. PubMed ID: 18976752
[TBL] [Abstract][Full Text] [Related]
12. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS).
Ganie MA; Hassan S; Nisar S; Shamas N; Rashid A; Ahmed I; Douhat S; Mudassar S; Jan VM; Rashid F
Gynecol Endocrinol; 2014 Nov; 30(11):781-4. PubMed ID: 25137507
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome.
Rossi B; Sukalich S; Droz J; Griffin A; Cook S; Blumkin A; Guzick DS; Hoeger KM
J Clin Endocrinol Metab; 2008 Dec; 93(12):4780-6. PubMed ID: 18812482
[TBL] [Abstract][Full Text] [Related]
14. Oxidative stress and cardiovascular complications in polycystic ovarian syndrome.
Hyderali BN; Mala K
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():15-22. PubMed ID: 26066290
[TBL] [Abstract][Full Text] [Related]
15. Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome.
Taskin MI; Bulbul E; Adali E; Hismiogulları AA; Inceboz U
Eur J Obstet Gynecol Reprod Biol; 2015 Jun; 189():19-23. PubMed ID: 25837320
[TBL] [Abstract][Full Text] [Related]
16. Metabolic and cardiovascular consequences of polycystic ovary syndrome.
Orio F; Vuolo L; Palomba S; Lombardi G; Colao A
Minerva Ginecol; 2008 Feb; 60(1):39-51. PubMed ID: 18277351
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives.
Cussons AJ; Stuckey BG; Watts GF
Atherosclerosis; 2006 Apr; 185(2):227-39. PubMed ID: 16313910
[TBL] [Abstract][Full Text] [Related]
18. Polycystic ovary syndrome and the metabolic syndrome.
Weerakiet S
J Med Assoc Thai; 2004 Oct; 87 Suppl 3():S189-93. PubMed ID: 21213522
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and comorbidities of polycystic ovary syndrome in an indigent population.
Sirmans SM; Parish RC; Blake S; Wang X
J Investig Med; 2014 Aug; 62(6):868-74. PubMed ID: 24844662
[TBL] [Abstract][Full Text] [Related]
20. Cardiometabolic aspects of polycystic ovarian syndrome.
Cho LW; Randeva HS; Atkin SL
Vasc Health Risk Manag; 2007; 3(1):55-63. PubMed ID: 17583175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
